Clinical Trials
9
Active:0
Completed:6
Trial Phases
4 Phases
Early Phase 1:2
Phase 1:2
Phase 2:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (44.4%)Early Phase 1
2 (22.2%)Phase 1
2 (22.2%)Phase 2
1 (11.1%)The Effects of Glucagon on Hepatic Metabolism
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 60
- Registration Number
- NCT05500586
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Phase 2
Recruiting
- Conditions
- Type2diabetes
- Interventions
- Behavioral: Caloric RestrictionDrug: Hyperglycemic clamp
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 20
- Registration Number
- NCT05499702
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
Phase 3
Completed
- Conditions
- HealthyType 2 Diabetes
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 23
- Registration Number
- NCT04466618
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
Phase 3
Recruiting
- Conditions
- Healthy
- Interventions
- Other: SalineBiological: Exendin-9,39
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 40
- Registration Number
- NCT04466566
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Drug: 0.4mU Insulin followed by withdrawal period followed by 0.8mU studyDrug: 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 12
- Registration Number
- NCT04461015
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
- Prev
- 1
- 2
- Next
News
No news found